{"id":5172,"date":"2024-06-10T14:12:44","date_gmt":"2024-06-10T06:12:44","guid":{"rendered":"https:\/\/regask.com\/?p=5172"},"modified":"2024-11-05T20:57:03","modified_gmt":"2024-11-05T12:57:03","slug":"le-vaccin-contre-le-chikungunya-approuve","status":"publish","type":"post","link":"https:\/\/regask.com\/fr\/chikungunya-vaccine-approved\/","title":{"rendered":"L&#039;EMA recommande l&#039;approbation du premier vaccin destin\u00e9 \u00e0 prot\u00e9ger\u2026"},"content":{"rendered":"<p>Le 31 mai 2024, l\u2019Agence europ\u00e9enne des m\u00e9dicaments (EMA) a annonc\u00e9 sa recommandation pour l\u2019approbation d\u2019Ixchiq, le premier vaccin con\u00e7u pour prot\u00e9ger les adultes contre le chikungunya, une maladie virale transmise par des moustiques infect\u00e9s.<\/p>\n<p>Cette avanc\u00e9e majeure marque une \u00e9tape importante dans le domaine de la sant\u00e9 publique, le chikungunya \u00e9tant devenu une pr\u00e9occupation croissante en raison de sa propagation rapide et des douleurs articulaires intenses qu&#039;il provoque. L&#039;approbation d&#039;Ixchiq repr\u00e9sente une nouvelle \u00e9tape dans les secteurs pharmaceutique et de la sant\u00e9, visant \u00e0 lutter contre la propagation de cette maladie invalidante.<\/p>\n<p><strong>Points saillants :<\/strong><\/p>\n<ul>\n<li><strong>Public cible :<\/strong> Le vaccin a \u00e9t\u00e9 autoris\u00e9 pour une utilisation chez les adultes, en ciblant un groupe d\u00e9mographique \u00e0 risque de contracter le chikungunya.<\/li>\n<li><strong>Impact mondial :<\/strong> Cette approbation introduit une mesure pr\u00e9ventive vitale contre une maladie qui a connu des \u00e9pid\u00e9mies dans le monde entier, soulignant le r\u00f4le essentiel de la vaccination dans le contr\u00f4le et la pr\u00e9vention de la maladie.<\/li>\n<li><strong>Conformit\u00e9 de l&#039;industrie :<\/strong> Les entreprises impliqu\u00e9es dans la production, la distribution ou l\u2019administration de vaccins devront mettre \u00e0 jour leurs cadres de conformit\u00e9 et r\u00e9glementaires pour int\u00e9grer ce nouveau vaccin, garantissant ainsi le respect des directives de l\u2019EMA.<\/li>\n<li><strong>Conseils en mati\u00e8re de sant\u00e9 :<\/strong> Les prestataires de soins et les \u00e9quipes de r\u00e9glementation doivent rester inform\u00e9s de la disponibilit\u00e9 du vaccin, de son utilisation recommand\u00e9e et des mises \u00e0 jour potentielles des calendriers de vaccination.<\/li>\n<li><strong>Surveillance continue :<\/strong> Les \u00e9quipes r\u00e9glementaires doivent \u00e9galement surveiller les recherches ou les mises \u00e0 jour ult\u00e9rieures concernant l\u2019efficacit\u00e9 et la s\u00e9curit\u00e9 du vaccin, car les \u00e9tudes en cours peuvent influencer les normes r\u00e9glementaires.<\/li>\n<\/ul>\n<p>L&#039;avis sera d\u00e9sormais transmis \u00e0 la Commission europ\u00e9enne en vue de l&#039;adoption d&#039;une d\u00e9cision d&#039;autorisation de mise sur le march\u00e9 \u00e0 l&#039;\u00e9chelle de l&#039;UE. Le demandeur d&#039;Ixchiq est Valneva Austria GmbH.<\/p>\n<p>&nbsp;<\/p>\n<p>&nbsp;<\/p>\n<a data-animate=\"fadeInLeft\" href=\"https:\/\/www.ema.europa.eu\/en\/news\/first-vaccine-protect-adults-chikungunya\" target=\"_blank\" class=\"button secondary is-link is-medium\" rel=\"noopener\" >\n\t\t<span>Lire l&#039;article complet<\/span>\n\t<\/a>\n\n<p>\u00a9Cette RegAlert est \u00e9mise par RegASK<\/p>","protected":false},"excerpt":{"rendered":"<p>On May 31, 2024, the European Medicines Agency (EMA) announced its recommendation for the approval of Ixchiq, the first vaccine designed to protect adults against chikungunya, a viral disease transmitted by infected mosquitoes. This groundbreaking development marks a significant milestone in public health, as chikungunya has been a growing concern due to its rapid spread&#8230;<\/p>","protected":false},"author":39,"featured_media":3960,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[35],"tags":[247,419,421,423,425],"class_list":["post-5172","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-pharma-biotech-latest-insights","tag-regulation-eu-legislation","tag-vaccine","tag-chikungunya","tag-ema","tag-market-authorization"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v28.0 (Yoast SEO v28.0) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Chikungunya Vaccine Approved by EMA | RegASK<\/title>\n<meta name=\"description\" content=\"EMA recommends approval of Ixchiq, the first vaccine to protect adults against chikungunya. Learn more about this breakthrough.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/regask.com\/fr\/le-vaccin-contre-le-chikungunya-approuve\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"EMA Recommends Approval of the First Vaccine to Protect Adults Against Chikungunya\" \/>\n<meta property=\"og:description\" content=\"EMA recommends approval of Ixchiq, the first vaccine to protect adults against chikungunya. Learn more about this breakthrough.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/regask.com\/fr\/le-vaccin-contre-le-chikungunya-approuve\/\" \/>\n<meta property=\"og:site_name\" content=\"RegASK\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/RegASKRegulatoryAffairs\/\" \/>\n<meta property=\"article:published_time\" content=\"2024-06-10T06:12:44+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-11-05T12:57:03+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/regask.com\/wp-content\/uploads\/2022\/10\/ema-recommends-approval-of-the-first-vaccine-to-protect-adults-against-chikungunya-870x653.png\" \/>\n\t<meta property=\"og:image:width\" content=\"870\" \/>\n\t<meta property=\"og:image:height\" content=\"653\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Benoit Trouwaert\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@ASKRegASK\" \/>\n<meta name=\"twitter:site\" content=\"@ASKRegASK\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Benoit Trouwaert\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/regask.com\\\/chikungunya-vaccine-approved\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/regask.com\\\/chikungunya-vaccine-approved\\\/\"},\"author\":{\"name\":\"Benoit Trouwaert\",\"@id\":\"https:\\\/\\\/regask.com\\\/#\\\/schema\\\/person\\\/c1d261e8dcf7b1c30b2c4f2c119df42d\"},\"headline\":\"EMA Recommends Approval of the First Vaccine to Protect&hellip;\",\"datePublished\":\"2024-06-10T06:12:44+00:00\",\"dateModified\":\"2024-11-05T12:57:03+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/regask.com\\\/chikungunya-vaccine-approved\\\/\"},\"wordCount\":282,\"publisher\":{\"@id\":\"https:\\\/\\\/regask.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/regask.com\\\/chikungunya-vaccine-approved\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/regask.com\\\/wp-content\\\/uploads\\\/2022\\\/10\\\/ema-recommends-approval-of-the-first-vaccine-to-protect-adults-against-chikungunya.png\",\"keywords\":[\"Regulation EU Legislation\",\"Vaccine\",\"Chikungunya\",\"EMA\",\"Market Authorization\"],\"articleSection\":[\"Pharma and Biotech\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/regask.com\\\/chikungunya-vaccine-approved\\\/\",\"url\":\"https:\\\/\\\/regask.com\\\/chikungunya-vaccine-approved\\\/\",\"name\":\"Chikungunya Vaccine Approved by EMA | RegASK\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/regask.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/regask.com\\\/chikungunya-vaccine-approved\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/regask.com\\\/chikungunya-vaccine-approved\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/regask.com\\\/wp-content\\\/uploads\\\/2022\\\/10\\\/ema-recommends-approval-of-the-first-vaccine-to-protect-adults-against-chikungunya.png\",\"datePublished\":\"2024-06-10T06:12:44+00:00\",\"dateModified\":\"2024-11-05T12:57:03+00:00\",\"description\":\"EMA recommends approval of Ixchiq, the first vaccine to protect adults against chikungunya. Learn more about this breakthrough.\",\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/regask.com\\\/chikungunya-vaccine-approved\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/regask.com\\\/chikungunya-vaccine-approved\\\/#primaryimage\",\"url\":\"https:\\\/\\\/regask.com\\\/wp-content\\\/uploads\\\/2022\\\/10\\\/ema-recommends-approval-of-the-first-vaccine-to-protect-adults-against-chikungunya.png\",\"contentUrl\":\"https:\\\/\\\/regask.com\\\/wp-content\\\/uploads\\\/2022\\\/10\\\/ema-recommends-approval-of-the-first-vaccine-to-protect-adults-against-chikungunya.png\",\"width\":1600,\"height\":1200,\"caption\":\"New Vaccine To Protect People In The Eu And Worldwide Against Dengue\"},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/regask.com\\\/#website\",\"url\":\"https:\\\/\\\/regask.com\\\/\",\"name\":\"RegASK\",\"description\":\"The Regulatory AI Operating System for High-Performing Teams\",\"publisher\":{\"@id\":\"https:\\\/\\\/regask.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/regask.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/regask.com\\\/#\\\/schema\\\/person\\\/c1d261e8dcf7b1c30b2c4f2c119df42d\",\"name\":\"Benoit Trouwaert\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Le vaccin contre le chikungunya approuv\u00e9 par l&#039;EMA | RegASK","description":"L&#039;EMA recommande l&#039;approbation d&#039;Ixchiq, le premier vaccin destin\u00e9 \u00e0 prot\u00e9ger les adultes contre le chikungunya. Apprenez-en plus sur cette avanc\u00e9e.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/regask.com\/fr\/le-vaccin-contre-le-chikungunya-approuve\/","og_locale":"fr_FR","og_type":"article","og_title":"EMA Recommends Approval of the First Vaccine to Protect Adults Against Chikungunya","og_description":"EMA recommends approval of Ixchiq, the first vaccine to protect adults against chikungunya. Learn more about this breakthrough.","og_url":"https:\/\/regask.com\/fr\/le-vaccin-contre-le-chikungunya-approuve\/","og_site_name":"RegASK","article_publisher":"https:\/\/www.facebook.com\/RegASKRegulatoryAffairs\/","article_published_time":"2024-06-10T06:12:44+00:00","article_modified_time":"2024-11-05T12:57:03+00:00","og_image":[{"width":870,"height":653,"url":"https:\/\/regask.com\/wp-content\/uploads\/2022\/10\/ema-recommends-approval-of-the-first-vaccine-to-protect-adults-against-chikungunya-870x653.png","type":"image\/png"}],"author":"Benoit Trouwaert","twitter_card":"summary_large_image","twitter_creator":"@ASKRegASK","twitter_site":"@ASKRegASK","twitter_misc":{"Written by":"Benoit Trouwaert","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/regask.com\/chikungunya-vaccine-approved\/#article","isPartOf":{"@id":"https:\/\/regask.com\/chikungunya-vaccine-approved\/"},"author":{"name":"Benoit Trouwaert","@id":"https:\/\/regask.com\/#\/schema\/person\/c1d261e8dcf7b1c30b2c4f2c119df42d"},"headline":"EMA Recommends Approval of the First Vaccine to Protect&hellip;","datePublished":"2024-06-10T06:12:44+00:00","dateModified":"2024-11-05T12:57:03+00:00","mainEntityOfPage":{"@id":"https:\/\/regask.com\/chikungunya-vaccine-approved\/"},"wordCount":282,"publisher":{"@id":"https:\/\/regask.com\/#organization"},"image":{"@id":"https:\/\/regask.com\/chikungunya-vaccine-approved\/#primaryimage"},"thumbnailUrl":"https:\/\/regask.com\/wp-content\/uploads\/2022\/10\/ema-recommends-approval-of-the-first-vaccine-to-protect-adults-against-chikungunya.png","keywords":["Regulation EU Legislation","Vaccine","Chikungunya","EMA","Market Authorization"],"articleSection":["Pharma and Biotech"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/regask.com\/chikungunya-vaccine-approved\/","url":"https:\/\/regask.com\/chikungunya-vaccine-approved\/","name":"Le vaccin contre le chikungunya approuv\u00e9 par l&#039;EMA | RegASK","isPartOf":{"@id":"https:\/\/regask.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/regask.com\/chikungunya-vaccine-approved\/#primaryimage"},"image":{"@id":"https:\/\/regask.com\/chikungunya-vaccine-approved\/#primaryimage"},"thumbnailUrl":"https:\/\/regask.com\/wp-content\/uploads\/2022\/10\/ema-recommends-approval-of-the-first-vaccine-to-protect-adults-against-chikungunya.png","datePublished":"2024-06-10T06:12:44+00:00","dateModified":"2024-11-05T12:57:03+00:00","description":"L&#039;EMA recommande l&#039;approbation d&#039;Ixchiq, le premier vaccin destin\u00e9 \u00e0 prot\u00e9ger les adultes contre le chikungunya. Apprenez-en plus sur cette avanc\u00e9e.","inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/regask.com\/chikungunya-vaccine-approved\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/regask.com\/chikungunya-vaccine-approved\/#primaryimage","url":"https:\/\/regask.com\/wp-content\/uploads\/2022\/10\/ema-recommends-approval-of-the-first-vaccine-to-protect-adults-against-chikungunya.png","contentUrl":"https:\/\/regask.com\/wp-content\/uploads\/2022\/10\/ema-recommends-approval-of-the-first-vaccine-to-protect-adults-against-chikungunya.png","width":1600,"height":1200,"caption":"New Vaccine To Protect People In The Eu And Worldwide Against Dengue"},{"@type":"WebSite","@id":"https:\/\/regask.com\/#website","url":"https:\/\/regask.com\/","name":"RegASK","description":"Le syst\u00e8me d&#039;exploitation d&#039;IA r\u00e9glementaire pour les \u00e9quipes performantes","publisher":{"@id":"https:\/\/regask.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/regask.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Person","@id":"https:\/\/regask.com\/#\/schema\/person\/c1d261e8dcf7b1c30b2c4f2c119df42d","name":"Beno\u00eet Trouwaert"}]}},"_links":{"self":[{"href":"https:\/\/regask.com\/fr\/wp-json\/wp\/v2\/posts\/5172","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/regask.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/regask.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/regask.com\/fr\/wp-json\/wp\/v2\/users\/39"}],"replies":[{"embeddable":true,"href":"https:\/\/regask.com\/fr\/wp-json\/wp\/v2\/comments?post=5172"}],"version-history":[{"count":0,"href":"https:\/\/regask.com\/fr\/wp-json\/wp\/v2\/posts\/5172\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/regask.com\/fr\/wp-json\/wp\/v2\/media\/3960"}],"wp:attachment":[{"href":"https:\/\/regask.com\/fr\/wp-json\/wp\/v2\/media?parent=5172"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/regask.com\/fr\/wp-json\/wp\/v2\/categories?post=5172"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/regask.com\/fr\/wp-json\/wp\/v2\/tags?post=5172"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}